# Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer

> **NCT03591276** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shaare Zedek Medical Center** · enrollment: 15 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Chemotherapy Drugs, Cancer

## Key facts

- **NCT ID:** NCT03591276
- **Lead sponsor:** Shaare Zedek Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-18
- **Primary completion:** 2021-04-15
- **Final completion:** 2021-06-15
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03591276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03591276, "Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03591276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*